BIOSYNEX

BIOSYNEX specializes in in vitro diagnostic (IVD) devices, including rapid diagnostic tests (RDTs), assays, and controls. Their portfolio covers infectious disease testing (e.g., respiratory pathogens, chlamydia), autoimmune monitoring (e.g., celiac disease screening via gluten or IgA detection), tumor marker assays (e.g., bladder cancer biomarkers), and drug monitoring controls (e.g., etanercept or rituximab levels). These products are designed for both professional and self-testing use, ensuring quick results and ease of use in clinical or home settings.

BIOSYNEX is headquartered in France, which places its IVD devices under the European Union’s regulatory framework. Since the company’s products are listed in the eudamed database, they comply with EU IVD directives (e.g., IVD General or self-testing-specific rules). The French location ensures alignment with EU regulatory requirements, including classification under Class A, B, C, I, IIa, or IIb, depending on risk level and intended use.

BIOSYNEX’s devices are registered in eudamed, the EU’s official database for medical devices. This listing is critical because it confirms compliance with EU IVD regulations, transparency for healthcare providers, and traceability for authorities. eudamed ensures that devices meet safety, performance, and labeling standards before entering the market, which is particularly relevant for IVDs that influence patient diagnosis or treatment decisions.

BIOSYNEX’s devices span multiple EU classifications: Class A/B/C (for general IVDs) and Class I/IIa/IIb (for specific diagnostic tests). Classifications determine risk levels—higher classes (e.g., IIb) require stricter validation for safety and accuracy, while lower classes (e.g., A) involve simpler regulatory pathways. For users, this means devices like self-testing kits (e.g., bladder tumor antigen tests) may have fewer pre-market hurdles than complex assays (e.g., celiac disease IgA monitoring), balancing accessibility with regulatory oversight.

BIOSYNEX produces self-testing IVDs like the Bladder Tumor Antigen test, designed for at-home use without professional interpretation. These differ from professional tests (e.g., FIDIS Celiac DPG IgA) in that they prioritize simplicity, speed, and minimal training—often classified as Class I or IIa—while professional versions may include additional validation steps (e.g., Class IIb) to ensure clinical precision. Self-tests are regulated under EU IVD self-testing directives to guarantee safety and reliability in non-professional settings.